Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

BCTC

TRPV1 antagonist
 
BML-CA231-0010 10 mg 84.00 USD
 
BML-CA231-0050 50 mg 334.00 USD
Do you need bulk/larger quantities?
 
BCTC is a potent and selective inhibitor of capsaicin-induced (IC50=35 nM) and acid-induced (IC50=6 nM) VR1 activation. It displays analgesic activity in rat models of inflammatory and neuropathic pain. TRPV1 antagonist.

Product Specification

Formula:C20H25ClN4O
 
MW:372.9
 
CAS:393514-24-4
 
Purity:≥98% (HPLC)
 
Appearance:Tan solid
 
MeltingPoint:150-152°C
 
Solubility:Soluble in DMSO (20 mg/ml) or ethanol (15 mg/ml with warming).
 
Shipping:Ambient
 
Long Term Storage:Ambient
 
bml-ca231
Please mouse over
bml-ca231

Product Literature References

N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties: K. J. Valenzano, et al.; J. Pharmacol. Exp. Ther. 306, 377 (2003), Abstract; Full Text
N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain: J. D. Pomonis, et al.; J. Pharmacol. Exp. Ther. 306, 387 (2003), Abstract; Full Text

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
TRP channel
By biological activity:
TRP channel Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,